These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21233426)

  • 1. The inverse benefit law: how drug marketing undermines patient safety and public health.
    Brody H; Light DW
    Am J Public Health; 2011 Mar; 101(3):399-404. PubMed ID: 21233426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug policy: making effective drugs available without bankrupting the healthcare system.
    Laupacis A; Anderson G; O'Brien B
    Healthc Pap; 2002; 3(1):12-30. PubMed ID: 12811107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reform of drug regulation--beyond an independent drug-safety board.
    Ray WA; Stein CM
    N Engl J Med; 2006 Jan; 354(2):194-201. PubMed ID: 16407517
    [No Abstract]   [Full Text] [Related]  

  • 4. Preventing postmarketing changes in recommended doses and marketing withdrawals.
    Peck C
    Ernst Schering Res Found Workshop; 2007; (59):209-16. PubMed ID: 17117726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
    Lexchin J
    CMAJ; 2005 Mar; 172(6):765-7. PubMed ID: 15767610
    [No Abstract]   [Full Text] [Related]  

  • 6. Post-marketing observational studies: my experience in the drug industry.
    BMJ; 2012 Jun; 344():e3990. PubMed ID: 22692654
    [No Abstract]   [Full Text] [Related]  

  • 7. The drugs industry: a bad product well marketed.
    Abbasi K
    J R Soc Med; 2012 Jul; 105(7):275. PubMed ID: 22843642
    [No Abstract]   [Full Text] [Related]  

  • 8. Unhealthy marketing of pharmaceutical products: An international public health concern.
    Mulinari S
    J Public Health Policy; 2016 May; 37(2):149-59. PubMed ID: 26911654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
    Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
    Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?
    Habibi R; Lexchin J; Mintzes B; Holbrook A
    Br J Clin Pharmacol; 2017 Nov; 83(11):2549-2556. PubMed ID: 28664660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Change of Reference to Post-Marketing Surveillance Based on the Sequence of Revising the Pharmaceutical Affairs Law.
    Takahashi H
    Yakushigaku Zasshi; 2016; 51(1):29-39. PubMed ID: 30183145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
    Smirniotopoulos A
    Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond the naïve "no-see": ethical prescribing and the drive for pharmaceutical transparency.
    Oldani M
    PM R; 2009 Jan; 1(1):82-6. PubMed ID: 19627878
    [No Abstract]   [Full Text] [Related]  

  • 15. Responsibility for pharmaceutical company samples.
    Reti S
    N Z Med J; 2005 May; 118(1215):U1472. PubMed ID: 15915193
    [No Abstract]   [Full Text] [Related]  

  • 16. Where Next for Opioids and the Law? Despair, Harm Reduction, Lawsuits, and Regulatory Reform.
    Burris S
    Public Health Rep; 2018; 133(1):29-33. PubMed ID: 29233069
    [No Abstract]   [Full Text] [Related]  

  • 17. Illicit Internet availability of drugs subject to recall and patient safety consequences.
    Mackey TK; Aung P; Liang BA
    Int J Clin Pharm; 2015 Dec; 37(6):1076-85. PubMed ID: 26148859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. If 'atypical' neuroleptics did not exist, it wouldn't be necessary to invent them: perverse incentives in drug development, research, marketing and clinical practice.
    Charlton BG
    Med Hypotheses; 2005; 65(6):1005-9. PubMed ID: 16182461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
    Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
    Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse event detection in drug development: recommendations and obligations beyond phase 3.
    Berlin JA; Glasser SC; Ellenberg SS
    Am J Public Health; 2008 Aug; 98(8):1366-71. PubMed ID: 18556607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.